King's Research Portal

DOI:

[10.1038/sj.bdj.2016.866](https://doi.org/10.1038/sj.bdj.2016.866)

Document Version

Peer reviewed version

[Link to publication record in King's Research Portal](#)

Citation for published version (APA):

de Souza, S., Bansal, R. K., & Galloway, J. (2016). Rheumatoid arthritis – an update for general dental practitioners. *British Dental Journal*, 221(10), 667-673. <https://doi.org/10.1038/sj.bdj.2016.866>

Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

Take down policy

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

Title page

Manuscript title

Rheumatoid arthritis – an update for general dental practitioners

Authors

Author 1 name: Dr Savia de Souza
Author 1 qualifications: BSc (Hons), BDS
Author 1 position/address: Honorary Patient Expert, Academic Rheumatology, King's College London, London.

Author 2 name: Dr Rupinder K. Bansal
Author 2 qualifications: BDS (Hons)
Author 2 positions/addresses: General Dental Practitioner, Springfield Dental Practice, Chelmsford. MSc Student, Dental Institute, King's College London, London.

Author 3 name: Dr James Galloway
Author 3 qualifications: MBChB, MSc, CHP, MRCP, PhD
Author 3 positions/addresses: Senior Clinical Lecturer, Academic Rheumatology, King's College London, London.
Honorary Consultant Rheumatologist, Rheumatology, King's College Hospital NHS Foundation Trust, London.

Corresponding author

Name: Dr Savia de Souza
Address: Department of Academic Rheumatology and Clinical Trials Group
Third Floor
Weston Education Centre
10 Cutcombe Road
London
SE5 9RJ
Email: savia.de_souza@kcl.ac.uk

Rheumatoid arthritis – an update for general dental practitioners

BACKGROUND

Rheumatoid arthritis (RA) is a common chronic inflammatory autoimmune condition which affects an estimated 400,000 UK adults.¹ Onset is commonly between 40-50 years old, though can occur at any age, with women three times more likely affected than men.¹ RA is a common cause of disability; work disability increases with age and disease duration.² RA results in increased healthcare costs and use of social security provision, as well as significantly reducing a patient's quality of life.^{3,4}

Pathophysiology

RA is characterised by the production of rheumatoid factor (RF) and anti-citrullinated protein antibody (ACPA) against autoantigens commonly expressed within and outside of synovial joints.⁵ RF is produced by B cells in the synovial membrane and is associated with more aggressive joint destruction.⁶ Traditionally, RF was the classic autoantibody in RA, however, ACPAs are now seen as being of increased importance as they are more specific and sensitive for RA diagnosis and predict a poorer disease course with progressive joint damage.⁷ RF, ACPA or both are present in 50-80% of people with RA.⁷

RA has several distinct disease subsets with several inflammatory cascades all resulting in persistent synovial inflammation with damage to articular cartilage and underlying bone.⁷ Key inflammatory cytokines in its pathogenesis are tumour necrosis factor- α (TNF- α) and interleukins 1 and 6 (IL-1, IL-6), which result in the production of proteolytic enzymes and activation of osteoclasts.⁶⁻⁸

Aetiology

It is thought RA occurs in response to environmental triggers in genetically susceptible individuals.⁵ The most recognised environmental trigger is smoking, which increases levels of the peptidyl arginine deiminase (PAD) enzyme responsible for protein citrullination (the conversion of arginine to citrulline).⁹ A recent study identified a clear dose-response relationship between smoking and the risk of developing RA.¹⁰ The periodontal pathogen *Porphyromonas gingivalis* has been implicated in the aetiology of RA as has, most recently, the gut microbiome.^{11,12} Other suggested environmental risk factors include region of birth, birthweight, breastfeeding and socioeconomic status.¹³ Genetic factors account for 50% of the risk of RA development, with more than 100 loci for genetic susceptibility identified to date.^{14,15} ACPA presence is associated with alleles containing a shared epitope (common protein-binding motif) in the HLA-DRB1 locus, and can be detected up to 15 years before RA onset.^{16,17}

Signs and symptoms

Common clinical features of RA include a symmetric polyarthritis with joint swelling (particularly in the hands and feet).¹⁸ Persistent joint inflammation (synovitis) results in bone and cartilage destruction which can ultimately lead to deformity, chronic pain and a loss of function.⁹ Patients can experience stiffness upon waking or after prolonged periods of rest.^{18,19} Systemic inflammation in RA can affect the brain (fatigue, reduced cognitive function and cerebrovascular events), liver (elevated acute-phase response and anaemia), heart (myocardial infarction and cardiac failure), lungs (inflammatory and fibrotic diseases), exocrine glands (secondary Sjögren's syndrome), bone (osteoporosis) and muscles (sarcopenia).²⁰ In severe RA, subcutaneous nodules and other extra-articular manifestations (such as vasculitis) can develop.¹⁸

Diagnosis

In 2010, the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR) jointly released new classification criteria for RA to assist rheumatologists with the diagnosis of newly-presenting patients.²¹ This assesses joint involvement, autoantibody status,

acute-phase reactants and symptom duration.⁷ Early diagnosis and initiation of intensive treatment prevents joint damage, and greatly improves functional outcome and morbidity for patients.¹⁸

Clinical assessment

Disease activity is often assessed using combined indices such as the Disease Activity Score based on the 28 joint count (DAS-28) which assesses joints in the hands, arms and knees for swelling and tenderness; measures the erythrocyte sedimentation rate (an inflammatory marker) and the patient's global assessment (a visual analogue scale-based score the patient gives for how RA is affecting them overall at that time).⁶ The Simplified Disease Activity Index (SDAI) or the Clinical Disease Activity Index (CDAI) are alternatives.⁶ X-rays, ultrasound and magnetic resonance imaging are all used to assess structural changes in the joints.⁶

Medical management

The aim of drug therapy is to reduce symptoms and suppress inflammation, thereby limiting joint damage and disability.²² Currently, it is recommended to follow a 'treat-to-target' strategy which involves initiating intensive drug therapy immediately after diagnosis and escalating this, guided by disease activity assessment, until clinical remission or low disease activity is achieved.^{20,22} Disease-modifying anti-rheumatic drugs (DMARDs) are the primary treatment used as they reduce pain and swelling of the joints, lower levels of acute-phase inflammatory markers, limit progressive joint damage and improve function.⁷ The first DMARD usually prescribed is methotrexate (sulfasalazine or leflunomide can be given if methotrexate is contraindicated).⁷ DMARDs can be used in combination to be more effective.²³

Conventional DMARDs modify the whole immune system, whereas biologic DMARDs target specific components within the inflammatory pathway.⁶ Biologic DMARDs are given to patients with persistently active disease, and are highly effective.²² They are usually prescribed for use in combination with methotrexate, as it is thought that this both reduces antibody formation to the biologic agent and increases its efficacy.⁷ Smoking reduces the efficacy of conventional DMARDs and smokers are more likely to fail on biologic therapies.²⁴

In RA, the pain response appears to be heightened; analgesics and non-steroidal anti-inflammatory drugs (NSAIDs) can be used for additional symptom control.^{7,25} Due to unfavourable side-effects, corticosteroid use is restricted to bridging therapy during acute flares of symptoms ('flare-ups') whilst awaiting DMARDs to reach full efficacy.⁷ Intra-articular injections are highly effective for disease suppression in individual active joints.⁷ New biologic DMARDs are currently in development, whilst biosimilar drugs and novel small molecule agents have come onto the market.^{6,22,26} The long-term effect of these drugs in clinical practice is yet to be determined. See Table 1. for a list of the most common drugs currently used to manage RA.

Having RA increases the risk of infections and this is raised further with the use of biologics.⁶ Biologic DMARDs have approximately a 30% increased chance of serious infection (e.g. tuberculosis) over conventional DMARD use, with this risk at its highest during the first six months of therapy.^{27,28} Other infection risks are bacterial (e.g. sepsis, abscesses and cellulitis), fungal (e.g. candidosis) and viral (e.g. shingles).^{7,29} Although there has been speculation about an increased risk of developing cancer with biologics use, a recent systematic review has shown this to be little or none.³⁰ In future, it may be possible to taper biologic DMARDs in select patients whose RA is in remission.³¹

Improved management of RA over the past two decades has resulted in a decline in its severity with less inflammatory biomarkers, extra-articular manifestations, hospital admissions and joint replacements.⁷ As better therapies have resulted in the reduction or absence of deformities, RA patients can appear quite 'normal'.³² For effective RA management, adjunct non-pharmacologic interventions are also advised (such as patient education, physiotherapy, occupational therapy, foot

care and psychological support) which are delivered by a multidisciplinary team of healthcare professionals.³³

Co-morbidities

Co-morbid conditions can be coincidental (with some already present at RA diagnosis), reflective of RA or its treatment.³⁴ RA patients have excess mortality from cardiovascular disease (CVD), but it remains unclear whether cardiovascular events are caused by inflammation associated with RA rather than traditional cardiac risk factors (such as hypertension, dyslipidemia and cigarette smoking).^{35,36} DMARDs are associated with a decreased risk of all cardiovascular events but this is increased with use of NSAIDs and corticosteroids.³⁷

After CVD, the second most common cause of mortality in RA is from cancer, particularly lymphoma and lung cancer.^{38,39} Patients with RA are more likely to develop skin cancer (non-melanoma and possibly melanoma) than the general population, and this risk may be increased by DMARD use.⁴⁰⁻⁴² RA patients have an increased risk of osteoporosis and resultant bone fractures linked to age, disease duration and steroid therapy.³⁸ Other co-morbidities include anaemia, depression, fibromyalgia, interstitial lung disease, Sjögren's syndrome, periodontal disease, diabetes mellitus and obesity.^{7,34,38,39,43-46}

It was previously reported that RA patients die prematurely from one or more comorbid diseases.⁴⁷ However, a recent study found that people who had RA onset after 2000, no longer have an increased risk of mortality compared to the general population.⁴⁸ This is likely due to improved treatments and tighter disease control over the last two decades. Overall, comorbidities increase disability levels, reduce a patient's quality of life, makes patient management more complex and increases the economic burden of disease.^{34,38}

ORAL HEALTH

Oral health complications due to RA and its treatments can cause additional problems for patients. A recent study found that approximately 30% of RA patients were taking additional analgesics specifically for oral pain.⁴⁹ Due to their immunosuppressive effects, RA medications can promote periodontitis, candidosis and oral ulceration aided by a lack of saliva.⁵⁰ The three main oral conditions associated with RA are discussed below:

Periodontal disease

Periodontal disease (PD) is a chronic inflammatory condition which leads to destruction of the periodontal ligament and alveolar bone, and can result in tooth loss.⁵¹ PD is caused by the presence of pathogenic gram-negative anaerobic bacteria within the biofilm attached to the sub-gingival tooth surface.⁹ *Porphyromonas gingivalis* (Pg) is the main pathogen in PD.⁹ Its virulence combined with an intense host immune response is thought to contribute to the severity of the disease.⁹

People with RA are almost twice as likely to have PD than those without.⁵² RA patients with severe PD have significantly higher DAS-28 scores than those with moderate or no periodontitis, and PD is associated with increased radiographic joint damage.^{53,54} These data strongly suggest an association between RA and PD/tooth loss. This association is independent of common risk factors such as smoking, alcohol intake, socioeconomic background and poor oral hygiene.⁵⁵

RA and PD are both chronic inflammatory diseases. Both conditions feature excessive destruction of collagen-rich tissues: in RA these are bone, cartilage and other periarticular tissues; in PD these are alveolar bone, periodontal ligament and gingiva.⁵⁶ Alveolar bone loss in PD results from the activation of osteoclasts and is very similar to bone erosion in RA, which is caused by cytokine-driven osteoclast activation.⁹

PD may be involved in the initiation and/or maintenance of systemic inflammation in RA.⁹ The level of Pg antibodies has been found to positively correlate with levels of ACPA in circulation in RA.⁵⁷ Pg is the only bacterium known to express a PAD enzyme, which can cause the citrullination of bacterial and host proteins.⁵⁸ This is thought to cause the body to produce ACPA, which drives the autoimmune response in RA.⁵⁸ PAD enzymes, citrullinated proteins and ACPA have all been found in inflamed gingiva.^{59,60} Antibodies to the periodontal pathogens Pg and *Prevotella intermedia* have been found in the serum and synovial fluid of patients whose RA is active.^{61,62}

Effective control of PD for RA patients is important to reduce both local and systemic inflammation, and the likelihood of bacteremia.⁶³ Persistent periodontitis can also reduce the effectiveness of TNF inhibitors.⁶⁴ Short-term clinical trials have demonstrated that non-surgical periodontal therapy in RA patients with PD, can decrease RA disease activity and systemic inflammation.⁶⁵⁻⁶⁷ Reduction in disease activity may be due to less inflammatory products, bacteria and endotoxins in the bloodstream after periodontal treatment, thereby reducing the exposure of joints to these products.^{68,69} Longer-term clinical trials are currently in progress to find out whether non-surgical periodontal treatment can lead to an improvement in clinical outcomes and quality of life for patients with active RA.⁷⁰ A recent systematic review also highlighted the importance of smoking cessation, which results in improved outcomes for non-surgical periodontal therapy.⁷¹

Temporomandibular dysfunction

The temporomandibular joint (TMJ) is used up to 2000 times a day for chewing and speaking, making it one of the most frequently used synovial joints in the body.⁷² People with RA have a higher frequency and greater severity of temporomandibular dysfunction (TMD) than the normal population.⁷³ The estimated prevalence of TMJ symptoms in adults with RA is between 5-86% (depending on diagnostic criteria, assessment methods and the population studied) with clinical involvement of the TMJ seen in about 50% of cases.^{73,74} In a 2013 survey of RA outpatients at a tertiary center, 45.8% had problems with chewing (with 40.3% having to adjust their diet accordingly), 30.6% felt discomfort when eating and 36.1% took medication to relieve oral pain.⁴⁹

RA patients with TMD may present with pain, difficulty with opening the mouth, 'locking' of the jaw, tenderness of the TMJ/masticatory muscles, and joint sounds.^{73,75} The most frequent joint sound is clicking, followed by crepitus (which indicates TMJ degeneration but may be seen less often due to improved RA medication).⁷⁶ It is thought that pain in TMD is associated with RA disease activity, and impairment in the range of motion and function of the TMJ are more likely due to degeneration of the joint.⁷³ Patients may also report associated symptoms such as ear pain/stiffness, tinnitus, dizziness, headache and neck pain.⁷⁷ *It is important to note that the TMJ may already be affected by RA in patients who do not yet report TMD symptoms.*⁷⁸

Clinical signs of TMJ involvement include swelling, reduced range of motion and/or deviation of the mandible to the affected side.⁷⁵ Imaging shows condylar resorption with a resultant shortening of the mandibular ramus-condyle unit and possibly a reduced joint space.⁷⁷ Cone-beam computed tomography (CBCT) imaging is best for showing the extent of condylar damage from RA, particularly in the early stages, and involves a lower radiation dose than conventional CT scans.⁷⁹ There is a positive correlation between the duration and severity of RA, and the degree of TMJ involvement.⁷⁸ Ankylosis of the TMJ is uncommon and occurs late in the disease course.⁷⁴ If ankylosis or collapse of the TMJ occurs, joint replacement may become necessary.⁷⁴ This has been shown to have good long-term outcomes for patients with inflammatory arthritis.⁸⁰ *TMD management in RA needs to involve the patient's rheumatologist and an oral & maxillofacial surgeon with an interest in TMJ diseases.*⁷⁴

Juvenile Idiopathic Arthritis (JIA), also known as Juvenile Rheumatoid Arthritis, affects around 12,000 children in the UK.⁸¹ The reported prevalence of TMJ arthritis in JIA ranges from 17 to 87%.⁸² Restricted mouth opening is the most frequent clinical finding (28% of patients) followed by masticatory muscle tenderness, deviation of the mandible on opening, TMJ tenderness and joint sounds.⁸² TMJ arthritis in

children can cause a disturbance of mandibular growth and evident alterations in craniofacial morphology and occlusion; features typically seen include an increased profile convexity, a steeper mandibular plane angle, mandibular micrognathia and retrognathia.⁸³

Inflammation occurs during the active phase of JIA, which ultimately causes resorption of the condyles.⁸² Damage to the condyles may be present early on in JIA and progress, even when clinical symptoms and signs are absent.⁸² The current gold standard method of imaging in JIA to detect early arthritic changes in the TMJ is magnetic resonance imaging (MRI) with contrast.⁸⁴ *Patients with JIA should have regular imaging of the TMJ and evaluation by an orthodontist, even in the absence of TMD signs and symptoms.*⁸²

Lastly, it is important to note that some patients with RA/JIA will have TMD that is unrelated to their inflammatory arthritis.

Salivary gland dysfunction

Sjögren's syndrome (SS) is a chronic autoimmune condition that is characterised by the sicca symptoms xerophthalmia and xerostomia, caused by inflammation leading to dysfunction of the lacrimal and salivary glands.⁸⁵ It can occur alone (primary form) or secondary to other systemic autoimmune diseases such as RA.⁸⁶ The estimated prevalence of sicca symptoms in RA patients ranges between 30-50%.⁸⁶

RA patients with SS have reduced salivary flow and altered saliva composition (due to destruction and dysfunction of the salivary glands).⁸⁷ This reduces the buffering and antimicrobial properties of saliva causing an increased likelihood of caries.⁸⁸ The subjective experience of xerostomia in SS is not dependent on the total quantity of saliva (salivary flow) but rather the quantity and quality of specific components within it (called mucins) which affect its ability to retain water.⁸⁷ Up to 70% of salivary mucins are produced by the minor salivary glands and overall they produce 10% of saliva.⁸⁹ Therefore, currently available treatments aimed solely at increasing salivary flow may not be sufficient to provide relief for SS patients.

Xerostomia can affect the oral cavity in many ways (see Table 2). Besides SS, a dry mouth can also be caused by medications taken by RA patients (see Table 1.). It is important to note that xerostomia may be reported by patients before obvious signs of hyposalivation are visible in the mouth.⁸⁷ *If a patient presents with a dry mouth and also complains of dry eyes, it is worth writing to their general medical practitioner (GP), or rheumatologist if they have a known rheumatic disorder, for further investigation.*

DENTAL MANAGEMENT

General considerations

Most RA patients can be successfully managed at the dental practice with some minor adjustments – see Table 3. for suggestions. Chronic inflammation of the cervical spine in RA can result in neck instability, which can cause neurological symptoms and in rare cases be fatal.⁹² *It is therefore important that a patient's head and neck are well supported during dental treatment. Suspected cervical instability should also be discussed with the patient's rheumatologist.*

Due to pain, impaired hand function and fatigue; RA patients may find it difficult and lack the motivation to follow a good oral hygiene regime (leading to further unfavourable outcomes).^{54,55,95,96} Good oral hygiene is the cornerstone for dental management of these patients, and aids should be recommended to making brushing and interdental cleaning easier for this population with poor grip and dexterity. Resources on suitable aids and adaptations are available.^{93,95} See Table 4. for a summary of management of common RA-associated dental problems. *If a patient is having recurrent problems due to their RA or medication, please discuss this with their rheumatologist or GP.*

Concurrent medications

As for any patient, it is important to take and keep updated a thorough medical/surgical history with a full medication list. Be aware of drug interactions when prescribing (particularly antibiotics); if in doubt consult the British National Formulary.¹⁰¹ If prescribing NSAIDs, check what the patient is already taking and assess toxicity risk.⁹⁴ Some RA patients take oral bisphosphonates for the prevention or treatment of osteoporosis; therefore, there is a small risk (estimated at 0.5%) of osteonecrosis of the jaw following dentoalveolar surgery.¹⁰² This risk can be increased with concomitant use of corticosteroids, and in some cases bisphosphonates may need to be stopped at least two months prior to surgery.¹⁰² Biologic DMARDs should be stopped much before major surgical procedures (according to the half-life of drug) so as not to increase infection risk.⁶ Conventional DMARDs may need to be stopped prior to procedures which last over an hour and it is recommended corticosteroid exposure be minimised prior to surgery.¹⁰³ *Therefore it is important to consult with the patient's rheumatologist well in advance of any planned invasive procedures and to follow up the patient postoperatively.*

Antibiotic and steroid cover

The National Institute for Health and Care Excellence's recently updated guidance is that patients considered at high risk of infective endocarditis do not routinely require antibiotic prophylaxis for dental procedures, though this may be appropriate in individual cases.¹⁰⁴ *If in doubt, consult with the patient's cardiologist.*

Latest guidelines from the British Society of Rheumatology state that pre-operative increase in steroid dose, for adrenal crisis prevention, is no longer routinely required.¹⁰³ However, if a patient shows signs of adrenal crisis (vomiting, abdominal pain, syncope, low blood pressure, hypoglycemia, confusion) during a procedure, *seek immediate emergency medical attention.*⁹⁴

Co-morbidity detection

Dentists should be aware of the potential co-morbidities with RA and *refer patients on to an appropriate medical professional for further investigation (copying in the patient's rheumatologist and GP) if they detect anything of concern.*

CONCLUSION

RA is a multi-faceted disease which can be complex to manage as co-morbid conditions are frequently present. Dental complications can arise associated with RA or its treatment. It is important that the dental team are aware of them so these patients can be successfully managed in general dental practice, with early intervention to prevent a further decline in their quality of life. Simple adjustments can be made to make dental visits more comfortable for patients with this long-term condition.

ACKNOWLEDGEMENTS

The authors would like to thank Tina Alvand, Rajvi Haria, Hiten Joshi, Heidi Lempp, Lydia Pink, Miranda Steeples and Ruth Williams for their manuscript feedback.

REFERENCES

1. NHS Choices. Rheumatoid arthritis. 2014. Online information available at <http://www.nhs.uk/conditions/Rheumatoid-arthritis/Pages/Introduction.aspx> (accessed May 2016)
2. de Croon E M, Sluiter J K, Nijssen T F, Dijkmans B A, Lankhorst G J, Frings-Dresen M H. Predictive factors of work disability in rheumatoid arthritis: a systematic literature review. *Ann Rheum Dis*. 2004; **63**: 1362-1367.
3. Boonen A, Severens J L. The burden of illness of rheumatoid arthritis. *Clin Rheumatol*. 2011; **30**: 3-8.
4. Lempp H, Scott D, Kingsley G. The personal impact of rheumatoid arthritis on patients' identity: a qualitative study. *Chronic Illn*. 2006; **2**: 109-120.
5. Boissier M C, Semerano L, Challal S, Saidenberg-Kermanac'h N, Falgarone G. Rheumatoid arthritis: from autoimmunity to synovitis and joint destruction. *J Autoimmun*. 2012; **39**: 222-228.
6. Scott D L. Biologics-based therapy for the treatment of rheumatoid arthritis. *Clin Pharmacol Ther*. 2012; **91**: 30-43.
7. Scott D L, Wolfe F, Huizinga T W. Rheumatoid arthritis. *Lancet*. 2010; **376**: 1094-1098.
8. Rengel Y, Ospelt C, Gay S. Proteinases in the joint: clinical relevance of proteinases in joint destruction. *Arthritis Res Ther*. 2007; **9**: 221.
9. Leech M T, Bartold P M. The association between rheumatoid arthritis and periodontitis. *Best Pract Res Clin Rheumatol*. 2015; **29**: 189-201.
10. Di Giuseppe D, Discacciati A, Orsini N, Wolk A. Cigarette smoking and risk of rheumatoid arthritis: a dose-response meta-analysis. *Arthritis Res Ther*. 2014; **16**: R61.
11. Kaur S, White S, Bartold P M. Periodontal disease and rheumatoid arthritis a systematic review. *J Dent Res*. 2013; **92**: 399-408.
12. Scher J U, Abramson S B. The microbiome and rheumatoid arthritis. *Nat Rev Rheumatol*. 2011; **7**: 569-578.
13. Liao K P, Alfredsson L, Karlson E W. Environmental influences on risk for rheumatoid arthritis. *Curr Opin Rheumatol*. 2009; **21**: 279.
14. van der Woude D, Houwing-Duistermaat J J, Toes R E, et al. Quantitative heritability of anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis. *Arthritis Rheum*. 2009; **60**: 916-923.
15. Yarwood A, Huizinga T W, Worthington J. The genetics of rheumatoid arthritis: risk and protection in different stages of the evolution of RA. *Rheumatology (Oxford)*. 2016; **55**: 199-209.

16. Huizinga T W, Amos C I, van der Helm-van Mil A, et al. Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins. *Arthritis Rheum.* 2005; **52**: 3433-3438.
17. van de Stadt L A, de Koning M H, van de Stadt R J, et al. Development of the anti-citrullinated protein antibody repertoire prior to the onset of rheumatoid arthritis. *Arthritis Rheum.* 2011; **63**: 3226-3233.
18. Davis J M, Matteson E L. My treatment approach to rheumatoid arthritis. *Mayo Clin Proc.* 2012; **87**: 659-673.
19. Centers for Disease Control and Prevention. Rheumatoid Arthritis (RA). 2015. Online information available at <http://www.cdc.gov/arthritis/basics/rheumatoid.htm> (accessed March 2016)
20. McInnes I B, Schett G. The pathogenesis of rheumatoid arthritis. *N Engl J Med.* 2011; **365**: 2205-2219.
21. Aletaha D, Neogi T, Silman A J, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. *Ann Rheum Dis.* 2010; **69**: 1580-1588. Erratum in: *Ann Rheum Dis.* 2010; **69**: 1892.
22. Gullick N J, Scott D L. Drug therapy of inflammatory arthritis. *Clin Med (Lond).* 2012; **12**: 357-363.
23. Ma M H, Scott I C, Kingsley G H, Scott D L. Remission in early rheumatoid arthritis. *J Rheumatol.* 2010; **37**: 1444-1453.
24. Daïen C I, Morel J. Predictive factors of response to biological disease modifying antirheumatic drugs: towards personalized medicine. *Mediators Inflamm.* 2014; **2014**: 386148.
25. Edwards R R, Wasan A D, Bingham III C O, et al. Enhanced reactivity to pain in patients with rheumatoid arthritis. *Arthritis Res Ther.* 2009; **11**: R61.
26. Galloway J. Biosimilars: Out of the laboratory and into practice. *Rheumatology (Oxford).* 2015; **54(suppl 1)**: i21.
27. Singh J A, Cameron C, Noorbaloochi S, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. *Lancet.* 2015; **386**: 258-265.
28. Galloway J B, Hyrich K L, Mercer L K, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. *Rheumatology (Oxford).* 2011; **50**: 124-131.
29. Galloway J B, Mercer L K, Moseley A, et al. Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. *Ann Rheum Dis.* 2013; **72**: 229-234.

30. Solomon D H, Mercer E, Kavanaugh A. Observational studies on the risk of cancer associated with tumor necrosis factor inhibitors in rheumatoid arthritis: a review of their methodologies and results. *Arthritis Rheum.* 2012; **64**: 21-32.
31. Galloway J B, Kingsley G, Ma M, et al. Optimising treatment with TNF Inhibitors in rheumatoid arthritis with different dose tapering strategies: The OPTTIRA trial. *Ann Rheum Dis.* 2015; **74(suppl 2)**: 706.
32. Prothero L, Georgopoulou S, de Souza S, Bearne L, Bosworth A, Lempp H. Patient involvement in the development of a handbook for moderate rheumatoid arthritis. *Health Expect.* 2016; [Epub ahead of print].
33. Christie A, Jamtvedt G, Dahm K T, Moe R H, Haavardsholm E A, Hagen K B. Effectiveness of nonpharmacological and nonsurgical interventions for patients with rheumatoid arthritis: an overview of systematic reviews. *Phys Ther.* 2007; **87**: 1697-1715.
34. Norton S, Koduri G, Nikiphorou E, Dixey J, Williams P, Young A. A study of baseline prevalence and cumulative incidence of co-morbidity and extra-articular manifestations in RA and their impact on outcome. *Rheumatology (Oxford).* 2013; **52**: 99-110.
35. Klareskog L, Catrina A I, Paget S. Rheumatoid arthritis. *Lancet.* 2009; **373**: 659-672.
36. Liao K P, Solomon D H. Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis. *Rheumatology (Oxford).* 2013; **52**: 45-52.
37. Roubille C, Richer V, Starnino T, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. *Ann Rheum Dis.* 2015; **74**: 480-489.
38. Gullick N J, Scott D L. Co-morbidities in established rheumatoid arthritis. *Best Pract Res Clin Rheumatol.* 2011; **25**: 469-483.
39. Simon T A, Thompson A, Gandhi K K, Hochberg M C, Suissa S. Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis. *Arthritis Res Ther.* 2015; **17**: 1-10.
40. Lange E, Blizzard L, Venn A, Francis H, Jones G. Disease-modifying anti-rheumatic drugs and non-melanoma skin cancer in inflammatory arthritis patients: a retrospective cohort study. *Rheumatology (Oxford).* 2016; [Epub ahead of print].
41. Assassi S. Rheumatoid arthritis, TNF inhibitors, and non-melanoma skin cancer. *BMJ.* 2016; **352**: i472.
42. Olsen C M, Hyrich K L, Knight L L, Green A C. Melanoma risk in patients with rheumatoid arthritis treated with tumour necrosis factor alpha inhibitors: a systematic review and meta-analysis. *Melanoma Res.* 2016; [Epub ahead of print].

43. Gabriel S E, Michaud K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. *Arthritis Res Ther*. 2009; **11**: 229.
44. Wolfe F, Michaud K. Anemia and renal function in patients with rheumatoid arthritis. *J Rheumatol*. 2006; **33**: 1516-1522.
45. Lempp H, Ibrahim F, Shaw T, et al. Comparative quality of life in patients with depression and rheumatoid arthritis. *Int Rev Psychiatry*. 2011; **23**: 118-124.
46. Whittaker M, Gullick N, Steer S et al. The association between obesity and disease activity in rheumatoid arthritis. *Rheumatology (Oxford)*. 2015; **54**(suppl 1): i65.
47. Gonzalez A, Maradit Kremers H, Crowson C S, et al. The widening mortality gap between rheumatoid arthritis patients and the general population. *Arthritis Rheum*. 2007; **56**: 3583-3587.
48. Lacaille D, Sayre E C, Abrahamowicz M. Improvement in mortality in RA compared to the general population – closing the mortality gap. *Arthritis Rheumatol*. 2015; **67**(suppl 10).
49. Blaizot A, Monsarrat P, Constantin A, et al. Oral health-related quality of life among outpatients with rheumatoid arthritis. *Int Dent J*. 2013; **63**: 145-153.
50. Araújo V M, Melo I M, Lima V. Relationship between periodontitis and rheumatoid arthritis: review of the literature. *Mediators Inflamm*. 2015; **2015**: 259074.
51. Eke P I, Dye B A, Wei L, et al. Update on prevalence of periodontitis in adults in the United States: NHANES 2009 to 2012. *J Periodontol*. 2015; **86**: 611-622.
52. de Pablo P, Dietrich T, McAlindon T E. Association of periodontal disease and tooth loss with rheumatoid arthritis in the US population. *J Rheumatol*. 2008; **35**: 70-76.
53. de Smit M, Westra J, Vissink A, Doornbos-van der Meer B, Brouwer E, van Winkelhoff A J. Periodontitis in established rheumatoid arthritis patients: a cross-sectional clinical, microbiological and serological study. *Arthritis Res Ther*. 2012; **14**: R222.
54. Monsarrat P, Vergnes J N, Blaizot A, et al. Oral health status in outpatients with rheumatoid arthritis: the OSARA study. *Oral Health Dent Manag*. 2014; **13**: 113-119.
55. Pischon N, Pischon T, Kröger J, et al. Association among rheumatoid arthritis, oral hygiene, and periodontitis. *J Periodontol*. 2008; **79**: 979-986.
56. Payne J B, Golub L M, Thiele G M, Mikuls T R. The link between periodontitis and rheumatoid arthritis: a periodontist's perspective. *Curr Oral Health Rep*. 2015; **2**: 20-29.
57. Mayer Y, Balbir-Gurman A, Machtei E E. Anti-tumor necrosis factor- α therapy and periodontal parameters in patients with rheumatoid arthritis. *J Periodontol*. 2009; **80**: 1414-1420.
58. Wegner N, Wait R, Sroka A, Eick S, et al. Peptidylarginine deiminase from *Porphyromonas gingivalis* citrullinates human fibrinogen and α -enolase: Implications for autoimmunity in rheumatoid arthritis. *Arthritis Rheum*. 2010; **62**: 2662-2672.

59. Nesse W, Westra J, Wal J E, et al. The periodontium of periodontitis patients contains citrullinated proteins which may play a role in ACPA (anti-citrullinated protein antibody) formation. *J Clin Periodontol.* 2012; **39**: 599-607.
60. Harvey G P, Fitzsimmons T R, Dhamarpatni A A, Marchant C, Haynes D R, Bartold P M. Expression of peptidylarginine deiminase-2 and-4, citrullinated proteins and anti-citrullinated protein antibodies in human gingiva. *J Periodontal Res.* 2013; **48**: 252-261.
61. Moen K, Brun J G, Valen M, et al. Synovial inflammation in active rheumatoid arthritis and psoriatic arthritis facilitates trapping of a variety of oral bacterial DNAs. *Clin Exp Rheumatol.* 2006; **24**: 656-663.
62. Martinez-Martinez R E, Abud-Mendoza C, Patiño-Marin N, Rizo-Rodríguez J C, Little J W, Loyola-Rodríguez J P. Detection of periodontal bacterial DNA in serum and synovial fluid in refractory rheumatoid arthritis patients. *J Clin Periodontol.* 2009; **36**: 1004-1010.
63. Otomo-Corgel J, Pucher J J, Rethman M P, Reynolds M A. State of the science: chronic periodontitis and systemic health. *J Evid Based Dent Pract.* 2012; **12**: 20-28.
64. Savioli C, Ribeiro A C, Fabri G M, et al. Persistent periodontal disease hampers anti-tumor necrosis factor treatment response in rheumatoid arthritis. *J Clin Rheumatol.* 2012; **18**: 180-184.
65. Ribeiro J, Leão A, Novaes A B. Periodontal infection as a possible severity factor for rheumatoid arthritis. *J Clin Periodontol.* 2005; **32**: 412-416.
66. Al-Katma M K, Bissada N F, Bordeaux J M, Sue J, Askari A D. Control of periodontal infection reduces the severity of active rheumatoid arthritis. *J Clin Rheumatol.* 2007; **13**: 134-137.
67. Ortiz P, Bissada N F, Palomo L, et al. Periodontal therapy reduces the severity of active rheumatoid arthritis in patients treated with or without tumor necrosis factor inhibitors. *J Periodontol.* 2009; **80**: 535-540.
68. D'Aiuto F, Nibali L, Parkar M, Suvan J, Tonetti M S. Short-term effects of intensive periodontal therapy on serum inflammatory markers and cholesterol. *J Dent Res.* 2005; **84**: 269-273.
69. Šimelyte E, Rimpiläinen M, Lehtonen L, Zhang X, Toivanen P. Bacterial cell wall-induced arthritis: chemical composition and tissue distribution of four *Lactobacillus* strains. *Infect Immun.* 2000; **68**: 3535-3540.
70. Vergnes J N, Monsarrat P, Blaizot A, et al. Interventions for periodontal disease in people with rheumatoid arthritis (Protocol). *Cochrane Database Syst Rev* 2012; **9**: CD010040.
71. Chambrone L, Preshaw P M, Rosa E F, et al. Effects of smoking cessation on the outcomes of non-surgical periodontal therapy: a systematic review and individual patient data meta-analysis. *J Clin Periodontol.* 2013; **40**: 607-615.

72. Ringold S, Cron R Q. The temporomandibular joint in juvenile idiopathic arthritis: frequently used and frequently arthritic. *Pediatr Rheumatol Online J*. 2009; **7**: 11.
73. Moen K, Bertelsen L T, Hellem S, Jonsson R, Brun J G. Salivary gland and temporomandibular joint involvement in rheumatoid arthritis: relation to disease activity. *Oral Dis*. 2005; **11**: 27-34.
74. Sidebottom A J, Salha R. Management of the temporomandibular joint in rheumatoid disorders. *Br J Oral Maxillofac Surg*. 2013; **51**: 191-198.
75. Mays J W, Sarmadi M, Moutsopoulos N M. Oral manifestations of systemic autoimmune and inflammatory diseases: diagnosis and clinical management. *J Evid Based Dent Pract*. 2012; **12**: 265-282.
76. Aliko A, Ciancaglini R, Alushi A, Tafaj A, Ruci D. Temporomandibular joint involvement in rheumatoid arthritis, systemic lupus erythematosus and systemic sclerosis. *Int J Oral Maxillofac Surg*. 2011; **40**: 704-709.
77. Scrivani S J, Keith D A, Kaban L B. Temporomandibular disorders. *N Engl J Med*. 2008; **359**: 2693-2705.
78. Celiker R, Gökçe-Kutsal Y, Eryilmaz M. Temporomandibular joint involvement in rheumatoid arthritis: relationship with disease activity. *Scand J Rheumatol*. 1995; **24**: 22-25.
79. Dawood A, Patel S, Brown J. Cone beam CT in dental practice. *Br Dental J*. 2009; **207**: 23-28.
80. O'Connor R C, Saleem S, Sidebottom A J. Prospective outcome analysis of total replacement of the temporomandibular joint with the TMJ Concepts system in patients with inflammatory arthritic diseases. *Br J Oral Maxillofac Surg*. 2016; [Epub ahead of print].
81. University of Manchester Centre for Musculoskeletal Research. Juvenile idiopathic arthritis. Online information available at <http://www.inflammation-repair.manchester.ac.uk/Musculoskeletal/research/CfGG/juvenilearthritis/> (accessed May 2016)
82. Billiau A D, Hu Y, Verdonck A, Carels C, Wouters C. Temporomandibular joint arthritis in juvenile idiopathic arthritis: prevalence, clinical and radiological signs, and relation to dentofacial morphology. *J Rheumatol*. 2007; **34**: 1925-1933.
83. Kjellberg H. Juvenile chronic arthritis. Dentofacial morphology, growth, mandibular function and orthodontic treatment. *Swed Dent J Suppl*. 1995; **109**: 1-56.
84. Vaid Y N, Dunnivant F D, Royal S A, Beukelman T, Stoll M L, Cron R Q. Imaging of the temporomandibular joint in juvenile idiopathic arthritis. *Arthritis Care Res (Hoboken)*. 2014; **66**: 47-54.
85. He J, Ding Y, Feng M, Guo J, et al. Characteristics of Sjögren's syndrome in rheumatoid arthritis. *Rheumatology (Oxford)*. 2013; **52**: 1084-1089.

86. Ramos-Casals M, Brito-Zerón P, Font J. The overlap of Sjögren's syndrome with other systemic autoimmune diseases. *Semin Arthritis Rheum*. 2007; **36**: 246-255.
87. Zalewska A, Knaś M, Waszkiewicz N, Waszkiel D, Sierakowski S, Zwierz K. Rheumatoid arthritis patients with xerostomia have reduced production of key salivary constituents. *Oral Surg Oral Med Oral Pathol Oral Radiol*. 2013; **115**: 483-490.
88. Zero D T, Brennan M T, Daniels T E, et al. Clinical practice guidelines for oral management of Sjögren disease: Dental caries prevention. *J Am Dent Assoc*. 2016; **147**: 295-305
89. Milne R W, Dawes C. The relative contributions of different salivary glands to the blood group activity of whole saliva in humans. *Vox Sang*. 1973; **25**: 298-307.
90. Guggenheimer J, Moore PA. Xerostomia: etiology, recognition and treatment. *J Am Dent Assoc*. 2003; **134**: 61-69.
91. Carr A J, Ng W F, Figueiredo F, Macleod R I, Greenwood M, Staines K. Sjögren's syndrome—an update for dental practitioners. *Br Dent J*. 2012; **213**: 353-357.
92. Gillick J L, Wainwright J, Das K. Rheumatoid arthritis and the cervical spine: a review on the role of surgery. *Int J Rheumatol*. 2015; [Epub ahead of print].
93. Bansal R K, Steeples M, de Souza S. Oral Health. National Rheumatoid Arthritis Society. 2015. Online information available at <http://www.nras.org.uk/oral-health> (accessed March 2016)
94. Patton L L, Glick M, eds. *The ADA practical guide to patients with medical conditions*. 2nd ed. New Jersey: Wiley-Blackwell, 2015.
95. Caesley, J. Interdental Cleaning in Rheumatoid Arthritis. *Dental Nursing*. 2014; **10**: 452-457.
96. Horsten N C, Ursum J, Roorda L D, van Schaardenburg D, Dekker J, Hoeksma A F. Prevalence of hand symptoms, impairments and activity limitations in rheumatoid arthritis in relation to disease duration. *J Rehabil Med*. 2010; **42**: 916-921.
97. Scottish Dental Clinical Effectiveness Programme. Prevention and Treatment of Periodontal Diseases in Primary Care Dental Clinical Guidance. 2015. Online information available at <http://www.sdcep.org.uk/wp-content/uploads/2015/01/SDCEP+Periodontal+Disease+Full+Guidance.pdf> (accessed May 2016)
98. Fox RI. Sjögren's syndrome. *Lancet*. 2005; **366**: 321-331.
99. Donaldson M, Epstein J, Villines D. Managing the care of patients with Sjögren syndrome and dry mouth: comorbidities, medication use and dental care considerations. *J Am Dent Assoc*. 2014; **145**: 1240-1247.
100. Gispen J G, Alarcon G S, Johnson J J, Acton R T, Barger B O, Koopman W J. Toxicity of methotrexate in rheumatoid arthritis. *J Rheumatol*. 1987; **14**: 74-79.

101. National Institute for Health and Care Excellence. British National Formulary. 2016. Online information available at <https://www.evidence.nhs.uk/formulary/bnf/current> (accessed May 2016)
102. Ruggiero S L, Dodson T B. American Association of Oral and Maxillofacial Surgeons position Paper on Medication-Related Osteonecrosis of the Jaws-2014 Update. *J Oral Maxillofac Surg.* 2014; **72**: 2381-2382.
103. Ledingham J, Gullick N, Irving K, et al. BSR/BHPR non-biologic DMARD guidelines. 2016. *Rheumatology (Oxford)* [in press]
104. National Institute for Health and Care Excellence. Prophylaxis against infective endocarditis: antimicrobial prophylaxis against infective endocarditis in adults and children undergoing interventional procedures. NICE Clinical Guideline No. 64. Updated 2016. Online information available at <https://www.nice.org.uk/guidance/cg64/chapter/Recommendations> (accessed August 2016)

Table 1. Drugs commonly used in RA management.^{6,22}

Drug class	Generic names												
Analgesics	Paracetamol Co-codamol Co-dydramol Tramadol												
NSAIDs	Ibuprofen Naproxen Diclofenac												
Corticosteroids	Prednisolone Methylprednisolone												
Conventional DMARDs	Methotrexate Leflunomide Sulfasalazine Hydroxychloroquine												
Biologic DMARDs	<table border="0"> <tr> <td>Adalimumab</td><td rowspan="5">} TNF inhibitors</td></tr> <tr> <td>Etanercept</td></tr> <tr> <td>Infliximab</td></tr> <tr> <td>Certolizumab pegol</td></tr> <tr> <td>Golimumab</td></tr> <tr> <td>Rituximab</td><td>– B-cell depletor</td></tr> <tr> <td>Abatacept</td><td>– T-cell costimulation inhibitor</td></tr> <tr> <td>Tocilizumab</td><td>– IL-6 inhibitor</td></tr> </table>	Adalimumab	} TNF inhibitors	Etanercept	Infliximab	Certolizumab pegol	Golimumab	Rituximab	– B-cell depletor	Abatacept	– T-cell costimulation inhibitor	Tocilizumab	– IL-6 inhibitor
Adalimumab	} TNF inhibitors												
Etanercept													
Infliximab													
Certolizumab pegol													
Golimumab													
Rituximab	– B-cell depletor												
Abatacept	– T-cell costimulation inhibitor												
Tocilizumab	– IL-6 inhibitor												
Small molecule agents	<table border="0"> <tr> <td>Tofacitinib</td><td>– JAK inhibitor</td></tr> <tr> <td colspan="2">[More to be licensed]</td></tr> </table>	Tofacitinib	– JAK inhibitor	[More to be licensed]									
Tofacitinib	– JAK inhibitor												
[More to be licensed]													

NSAIDs = Non-steroidal anti-inflammatory drugs. DMARDs = Disease-modifying anti-rheumatic drugs. TNF = Tumour necrosis factor. IL-6 = Interleukin-6. JAK = Janus kinase.

Table 2. Oral signs and symptoms of Sjögren's Syndrome.^{75,88,90,91}

Signs	Symptoms
<ul style="list-style-type: none">• Enlarged parotid glands• Absence of saliva pooling in floor of mouth• Dry/cracked oral mucosa and lips• Mouth sores• Increased caries incidence (especially cervical)• Increased dental erosion• Erythematous cobblestoned/fissured tongue• Atrophy of filiform papillae• Coated tongue ('black hairy tongue')• Candidosis• Halitosis• Difficulty with denture retention	<ul style="list-style-type: none">• Soreness• Burning• Loss of/altered taste sensation• Difficulty with eating• Difficulty with swallowing• Difficulty with speaking• Pain from denture-induced irritation

Table 3. Suggestions to make dental visits more comfortable for RA patients.^{93,94}

Before treatment	<ul style="list-style-type: none">• Organise appointments at times more suitable for the patient's condition. e.g. if they experience morning stiffness, schedule visits for the afternoon.• Make shorter, more frequent appointments rather than lengthy visits where patients can experience stiffness in the dental chair.• Book a treatment room with step-free access.
During treatment	<ul style="list-style-type: none">• Adjust the dental chair and headrest to a comfortable position, as RA patients can get considerable neck pain and stiffness during treatment.• Offer the patient a small pillow or allow them to bring their own.• Allow the patient to rest and move their jaw periodically during treatment to prevent pain, fatigue and stiffness from keeping their jaw open for prolonged periods.• Reassure the patient that they can ask to take a break at any time.• Ask the patient if they require any other adjustments.

Table 4. Summary of suggested management for RA-associated dental problems.^{74,75,77,88,90,91,93-95,97-100}

Dental problem	Management
Periodontal disease	<ul style="list-style-type: none"> • More frequent dental/hygiene visits • Regular scaling and root planing (no adjuncts necessary) • Oral hygiene instruction – recommend electric toothbrushes and interdental cleaning aids with wider handles • Smoking cessation advice and support • Refer to a periodontist if necessary
Temporomandibular dysfunction	<ul style="list-style-type: none"> • Jaw rest • Warm compress application • Physiotherapy • Soft food diet • Short-term NSAID use (topical or systemic) • Occlusal splint (soft or hard) wear at night time • Biobehavioural therapy • Elimination of unhelpful habits e.g. nail biting, wide yawning • Discuss with patient's rheumatologist/GP if TMJ arthritis suspected • Refer to oral & maxillofacial surgery and orthodontics (for children) if necessary
Salivary gland dysfunction	<ul style="list-style-type: none"> • More frequent dental visits • Medication review • Advise to keep hydrated with regular sipping of water • Smoking cessation advice • Chew sugar-free gum or lozenges regularly (if no TMJ problems) • Oral hygiene instruction • Pit and fissure seal teeth • Fluoride varnish, prescription-strength toothpaste or mouthwash • Use of non-fluoride remineralising agents e.g. calcium phosphate rinse • Chlorhexidine varnish, gel or mouth rinse • Advise to reduce sugar/acid intake and frequency • Salivary replacement (gels, mouth rinses, toothpastes, lozenges) • Advise patient to use a humidifier, particularly when sleeping • Discuss with patient's rheumatologist/GP • Prescribe salivary stimulants e.g. pilocarpine • Refer to oral medicine if necessary • Refer to GP/rheumatologist if an undiagnosed underlying rheumatic disease is suspected
Oral candidosis/ Angular cheilitis	<ul style="list-style-type: none"> • Prescribe topical or systemic antifungals • Discourage denture wear at night • Encourage good denture hygiene
Oral ulceration	<ul style="list-style-type: none"> • Check patient is taking medication (especially methotrexate) at the prescribed dose and interval • Prescribe benzydamine mouthwash/oromucosal spray • Urgent referral to oral medicine if ulcers are longstanding (> 3 weeks) or suspicious

NSAID = Non-steroidal anti-inflammatory drug. GP = General medical practitioner. TMJ = Temporomandibular joint.